Regencell Bioscience Holdings Limited (RGC) quarterly cash flow statement — complete operating, investing & financing history
Regencell Bioscience Holdings Limited (RGC) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | Q4'26 | Q2'26 | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 | Q4'21 | Q2'21 | Q4'20 | Q2'20 |
|---|
| Cash from Operations | -5.1M | -2.59M | 0 | 0 | -2M | -4M | -2.48M | -4.96M | -2.63M | -5.27M | -196.77K | -186.88K | -204.92K | -158.37K |
| Operating CF Margin % | - | - | - | - | - | - | - | - | 0.11% | - | - | - | - | - |
| Operating CF Growth % | - | - | 100% | 100% | 19.37% | 19.37% | 5.77% | 5.77% | -1238.36% | -2718.37% | 3.98% | -18.01% | - | - |
| Net Income | -6.38M | -5.32M | -1.73K | -1.85K | -2.18M | -4.36M | -2.94M | -6.06M | -3.72M | -7.59M | -506.45K | -166.92K | -257.18K | -149.01K |
| Depreciation & Amortization | 363.7K | 40.84K | 0 | 51.76K | 159.21K | 745.59K | 769.69K | 769.69K | 604.4K | 604.4K | 6.56K | 6.67K | 4.76K | 0 |
| Stock-Based Compensation | 0 | 1.64M | -35 | 280 | 224.66K | 449.31K | 465K | 922.62K | 1.38M | 2.76M | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 916.29K | 1.05M | 1.76K | -50.18K | 89.58K | -248K | -526.12K | -83.98K | -381.87K | -10.73K | 0 | -1 | 0 | 0 |
| Working Capital Changes | 0 | 0 | 0 | 0 | -292.68K | -585.37K | -254.47K | -508.94K | -512.03K | -1.02M | 303.12K | -26.63K | 47.5K | -9.36K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 0 | 2.5M | 0 | 0 | 2.62M | 5.24M | 29.49K | 58.98K | -5.39M | -10.78M | 7.64K | -7.64K | -33.28K | -25.64K |
| Capital Expenditures | 0 | 0 | 0 | 0 | -2.69K | -5.38K | -13.7K | -27.39K | -390.44K | -780.88K | 7.64K | -7.64K | -33.28K | -25.64K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | -0.02% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 43.19K | 970 | -5M | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 16.95M | 0 | 0 | 0 | 51.14K | 102.28K | 67.46K | 134.91K | 11.2M | 22.41M | 65.87K | 154.01K | -1.72K | 495.76K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -431.97K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 16.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22.67M | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -1.78M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 51.14K | 102.28K | 67.46K | 134.91K | 11.2M | 164K | 65.87K | 154.01K | -1.72K | 495.76K |
| Net Change in Cash | 11.84M | -61.9K | 2.42M | -2.96M | 1.4M | 1.4M | -4.85M | -4.85M | 6.36M | 6.36M | -228.74B | 306 | -239.92K | 311.76K |
| Free Cash Flow | -5.1M | -2.59M | 0 | 0 | -2M | -4.01M | -2.5M | -4.99M | -3.02M | -6.05M | -189.14K | -194.52K | -238.2K | -184.01K |
| FCF Margin % | - | - | - | - | - | - | - | - | 0.13% | - | - | - | - | - |
| FCF Growth % | - | - | 100% | 100% | 19.7% | 19.7% | 17.49% | 17.49% | -1498.82% | -3009.17% | 20.6% | -5.71% | - | - |
| FCF per Share | -0.01 | -0.01 | - | - | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.49x | - | - | 1791.26x | 3872.68x | 0.94x | 1.54x | 0.67x | 1.44x | 388.53x | 1119.57x | 796.80x | 1062.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |